Citations

Clear

7 citation(s) found for "Akhtar, Saad".

Historical outcomes for patients with stage IA NLPHL: Global NLPHL One Working Group retrospective analyses
Flerlage, Jamie E. , Eichenauer, Dennis A. , Fuchs, Michael, Hartmann, Sylvia , Eich, Hans Theodor, Savage, Kerry J. , Skinnider, Brian, Akhtar, Saad , Steiner, R., Milgrom, Sarah A., Vega, Francisco, Alomari, Mohammed , Zhang, Xiaoyin , Collins, Graham P., Advani, Ranjana H, Kumar, Priyadarshini , Wirth, Andrew, Tsang, Richard, Smith, SD, Hendrickson, Peter G. , Hopkins, David, McKay, Pamela, Ng, Andrea K. , Koenig, Julie L. , Sakthivel, Gukan, Baron, Jonathan A, Roberts, Kenneth B. , Gao, Sarah, Alkendi, Jalila , Rahbi, Nasser Al, Balogh, Alexander George, Ricardi, Umberto, Sridhar, Akshay, Torka, Pallawi , Specht, Lena , Silva, Ravi De , Shah, Nimish, Osborne, Wendy , Henry, Michael, Chang, Isabela , Halperin, Daniel, Miall, Fiona , Brady, J.L. , Mikhaeel, G., Brennan, Bernadette , Penn, Anthony, Reeves, Marie, Terezakis, Stephanie A, Pepa, R Della, Picardi, Marco, Kirova, Youlia, Fergusson, Paige, Hawkes, Eliza A. , Lee, Denise , Ku, Matthew , Hamad, Nada, Mutsando, Howard , Tedjaseputra, Aditya , Gilbertson, Michael, Marconi, Tamara , Viiala, Nicholas , Palese, Monica , Kelly, Kara M, Borchmann, P, Hoppe, Richard T. , Advani, Ranjana H. , Hopkins, David , Baron, Jonathan , Vega, Francisco , Kumar, Priyadarshini , Dickinson, Michael , Smith, Sonali M , McKay, Pamela , Koenig, Julie , Casulo, Carla , Al Kendi, Jalila , Levis, Mario , Torka, Pallawi , Specht, Lena , De Silva, Ravindu , Pickard, Keir , Smith, Christine M , Brady, Jessica , Senchenko, Maria Anatolevna , Volchkov, Egor Vasilevich , Hoppe, Bradford S , Hawkes, Eliza , Lee, Denise , Doo, Nicole Wong , Barraclough, Allison , Cheah, Chan Yoon , Salvaris, Ross , Ku, Matthew , Hamad, Nada , Tedjaseputra, Aditya , Shankar, Ananth , Maurer, Matthew , Natkunam, Yasodha , Hoppe, Richard T , Binkley, Michael Sargent , Savage, Kerry J , Advani, Ranjana H , Hopkins, David , Baron, Jonathan , Eichenauer, Dennis A , Flerlage, Jamie E , Fuchs, Michael, Eich, Hans Theodor, Hodgson, David C. , Skinnider, Brian, Rauf, M. Shahzad , Maghfoor, Irfan , Pinnix, Chelsea C. , Alomari, Mohammed, Collins, Graham P. , Dickinson, Michael , Tsang, Richard , Prica, Anca A. , Major, Ajay , Kelsey, Chris R. , Constine, Louis S , Casulo, Carla , Plastaras, John Peter , Balogh, Alexander G., Levis, Mario , Ricardi, Umberto , Sridhar, Akshay, Shah, Nimish , Pickard, Keir , Blazin, Lindsay , Henry, Michael, Smith, Christine M. , Hoppe, Bradford S. , Talaulikar, Dipti , Pepa, Roberta Della , Picardi, Marco , Kirova, Youlia , Northend, Michael , Doo, Nicole Wong , Barraclough, Allison , Opat, Stephen , Cheah, Chan Y. , Hamad, Nada , Gilbertson, Michael , Maurer, Matthew J. , Natkunam, Yasodha , Kelly, Kara M. , Borchmann, Peter , Binkley, Michael S.

Mayo Clinic

Blood Advances | April 14, 2026 | Volume: 10 | Issue: 15 | Pages: 5338-5347

10.1182/bloodadvances.2026020012 | PMID 41979337 Get It

Abstract We evaluated outcomes by management type for patients with stage IA nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) in the Global NLPHL One Working Group retrospective database of 2243 patients with stages I to IV disease diagnosed from 1992 to 2021 at 38 international institutions. A total of 779 patients had stage IA disease with median age of 35 years (range, 3-89) and median follow-up of 6.1 years. The 6-year progression-free survival (PFS) and overall survival were 86.3% and 97.7%, respectively. Outcomes were analyzed for the 2 groups: complete resection and unresected disease. Patients with a complete resection and observation alone (n = 99) had a 6-year PFS of 65.5% vs 90.5% for those who received radiotherapy (RT) (n = 53). Patients with unresected disease (n = 627; 80.5%) had a 6-year PFS of 62.0% for rituximab alone (n = 31), 89.6% for RT alone (n = 325), 76.8% for ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) alone (n = 40), and 94.3% for ABVD plus RT (n = 130). A total of 127 patients relapsed (16.3%), of which 25 (19.7%) had transformation. Our analysis suggests the following: (1) RT improves the PFS in patients with completely resected disease; (2) rituximab or ABVD alone does not appear to achieve a durable response; and (3) chemotherapy was not observed to add additional PFS benefit when used in combination with RT. Thus, for stage IA NLPHL, RT alone is likely sufficient for definitive treatment.
SURP-02. Re-ETV versus Ventriculoperitoneal Shunting in Failed ETV in Pediatric Patients with Hydrocephalus: A Systematic Review
Ahmed, Ikhlas , Choudry, Usama Khalid , Basit, Abdul , Nasir, Roua , Noor, Ahmed , Pasha, Muhammad Saad, Akhunzada, Naveed Zaman, Arif, Aabiya , Godfrey, Oswin, Nathani, Karim Rizwan , Khan, Saad Akhtar , Haque, Minza, Noor, Ahmed

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v418-v419

10.1093/neuonc/noaf201.1657 Get It

Abstract INTRODUCTION Hydrocephalus in pediatric patients is commonly treated with endoscopic third ventriculostomy (ETV) or ventriculoperitoneal shunting (VPS). When primary ETV fails, clinicians must decide between repeat ETV (Re-ETV) and VPS placement. However, the optimal secondary intervention remains debated. Objective: To compare the efficacy and outcomes of Re-ETV versus VPS placement following failed primary ETV in pediatric hydrocephalus. METHODS We conducted a systematic review following PRISMA guidelines. Searches of PubMed, Embase, and the Cochrane Library identified English-language studies (2001–2023) reporting on Re-ETV or VPS after failed primary ETV in patients aged 0–18 years. Comparative studies, including randomized controlled trials, cohort studies, and prospective designs were eligible. Two independent reviewers screened titles, abstracts, and full texts; extracted data on sample size, intervention rates, failure rates, and complications; and assessed study quality using RoB 2.0 and CASP tools. Pooled descriptive statistics and odds ratios (OR) were calculated for secondary intervention failure. RESULTS Nine studies (n = 663) met inclusion criteria. Re-ETV was performed in 220 patients (33.2%) and VPS in 443 (66.8%). Primary ETV failure rates ranged from 16.6% to 60.9% (mean 40.6%). Re-ETV exhibited a pooled failure rate of 74.98%, whereas VPS failure was 22.26% (OR 4.86; 95% CI 3.21–7.38; p < 0.05). Hemorrhagic etiology during primary ETV significantly favored VPS over Re-ETV (p < 0.05). Time to secondary failure averaged 15.8 ± 21.7 months, with broad inter-study variability. CONCLUSION VPS placement demonstrates a substantially lower failure rate than Re-ETV as a secondary intervention after primary ETV failure in pediatric hydrocephalus. Nevertheless, variability in patient age, etiology, and follow-up underscores the necessity of individualized decision-making. Prospective trials with standardized outcome measures are warranted to refine secondary treatment guidelines.
23 | RADIOTHERAPY IMPROVES PROGRESSION‐FREE SURVIVAL FOR STAGE IA NLPHL: A RETROSPECTIVE REPORT FROM THE GLOBAL NLPHL ONE WORKING GROUP (GLOW)
Hartmann, S., Eich, Hans‐Theodor, Skinnider, Brian, Akhtar, Saad , Steiner, R., Milgrom, Sarah A. , Alomari, Mohammed H., Zhang, X., Wirth, A., Tsang, Rky, Smith, Sonali M. , Hendrickson, P., Hopkins, David , Ng, A., Koenig, Julie L. , Casulo, Carla , Sakthivel, GD, Roberts, Kenneth B. , Gao, Sarah , Alkendi, Jalila , Rahbi, Nasser Al, Balogh, Alex, Ricardi, U., Torka, Pallawi , Silva, Ravi De , Shah, Nimish , Osborne, Wendy , Henry, M M , Miall, Fiona , Brady, J.L. , Mikhaeel, G., Brennan, Barbara J. , Penn, Andrew M. , Reeves, Michael A., Terezakis, S., Kirova, Youlia , Fergusson, Pamela, Lee, Denise , Ku, Matthew , Mutsando, Howard , Tedjaseputra, Aditya , Gilbertson, Michael , Marconi, Tamara , Viiala, Nicholas , Natkunam, Y., Kelly, Kara M. , Borchmann, Peter , Hoppe, R T, Binkley, Michael S., Hopkins, David , Ku, Matthew , Flerlage, Jamie E. , Eichenauer, Dennis A. , Fuchs, M., Hartmann, S., Savage, Kerry J. , Hodgson, David C. , Rauf, M. Shahzad , Maghfoor, Irfan , Pinnix, Chelsea C. , Vega, Francisco , Alomari, M., Zhang, X., Collins, Graham P. , Advani, Ranjana H. , Kumar, P., Dickinson, Michael , Tsang, R., Prica, Anca A. , Major, Ajay , Kelsey, Chris R. , McKay, Pamela , Constine, Louis S , Casulo, Carla , Baron, J., Plastaras, John Peter , Levis, Mario , Sridhar, A., Specht, Lena , Pickard, Keir , Blazin, Lindsay , Henry, M., Chang, I., Smith, Christine M , Halperin, Daniel M. , Brennan, B., Penn, A., Senchenko, Maria Anatolevna , Volchkov, Egor Vasilevich , Hoppe, Bradford S. , Talaulikar, Dipti , Pepa, Roberta Della , Picardi, Marco , Fergusson, P., Northend, Michael , Hawkes, Eliza A. , Doo, Nicole Wong , Barraclough, Allison , Opat, Stephen , Cheah, Chan Y. , Salvaris, Ross , Hamad, Nada , Palese, M., Shankar, Ananth , Maurer, Matthew J. , Binkley, Michael S.

Mayo Clinic

Hematological Oncology | June 16, 2025 | Volume: 43 | Issue: S3 | Pages: No page available

10.1002/hon.70093_23 Get It

Re-endoscopic third ventriculostomy versus ventriculoperitoneal shunting in failed endoscopic third ventriculostomy in pediatric patients with hydrocephalus: A systematic review
Ahmed, Ikhlas , Choudry, Usama Khalid , Basit, Abdul , Nasir, Roua , Noor, Ahmed , Pasha, Muhammad Saad, Arif, Aabiya , Akhunzada, Naveed Zaman, Godfrey, Oswin, Sangah, Abdul Basit , Nathani, Karim Rizwan , Khan, Saad Akhtar , Haque, Minza, Noor, Ahmed

Mayo Clinic

Surgical Neurology International | May 30, 2025 | Volume: 16 | Issue: No issue available | Pages: 205

10.25259/sni_1111_2024 | PMID 40469369 Get It

Background: The objective of this research article is to compare endoscopic treatment versus shunting procedures for failed endoscopic third ventriculostomies (ETVs) in pediatric patients with hydrocephalus. Methods: We did a systematic review based on preferred reporting items for systematic reviews and meta-analyses guidelines on Studies involving pediatric patients (aged 0–18 years) diagnosed with hydrocephalus, reporting on the use of repeat ETV (Re-ETV) or Ventriculoperitoneal shunting (VPS) as a treatment option following failed ETV. Comparative studies, including randomized controlled trials, cohort studies, and any prospective studies, are included. Studies published in the English language conducted between 2001 and 2023 are included. Results: Forty articles were selected for full-text review. Out of which nine articles that clearly addressed the topic of Re-ETV and/or VPS placement after failure of primary ETV were deemed suitable for analysis. A data set of 663 patients was analyzed. Re-ETV was done in 220 patients (33.18%) and VPS Placement was done in 443 patients (66.81%). The primary ETV failure rates ranged from 16.6 to 60.89%. There was a higher failure rate of Re-ETV (74.98%) compared to VPS (22.26%) indicating that VPS is generally more successful as a secondary intervention. The presence of hemorrhage during primary ETV suggested more benefit from VPS placement rather than Re-ETV (P < 0.05). Conclusion: Our systematic review suggests that VPS placement is the more prevalent choice after primary ETV failure, likely due to its higher overall success rate and the nature of complications. The wide variability in failure rates and follow-up durations suggests that treatment outcomes can differ greatly between patients and studies. Decisions regarding secondary interventions should be individualized, considering patient-specific factors such as age, complications, and timing of intervention.
International Prognostic Score for Nodular Lymphocyte–Predominant Hodgkin Lymphoma
Binkley, Michael S. , Flerlage, Jamie E. , Savage, Kerry J. , Akhtar, Saad , Steiner, Raphaël , Zhang, Xiaoyin , Dickinson, Michael , Major, Ajay , Hendrickson, Peter G. , Hopkins, David , Ng, Andrea K. , Casulo, Carla , Baron, Jonathan , Roberts, Kenneth B. , Alkendi, Jalila , Balogh, Alex, Torka, Pallawi , Specht, Lena , Silva, Ravi De , Pickard, Keir , Henry, M M , Smith, Christine M. , Brady, J.L. , Brennan, Bernadette , Сенченко, М. А. , Reeves, Marie, Terezakis, Stephanie , Fergusson, Paige, Hawkes, Eliza A. , Lee, Denise , Barraclough, Allison , Cheah, Chan Y. , Ku, Matthew , Mutsando, Howard , Gilbertson, Michael , Marconi, Tamara , Viiala, Nicholas , Hoppe, Richard T. , Borchmann, Peter , Fuchs, Michael , Hartmann, Sylvia , Eich, Hans Theodor, Skinnider, Brian, Milgrom, Sarah A. , Alomari, Mohammed H., Advani, Ranjana H. , Metzger, Monika L. , Wirth, Andrew, Smith, Sonali M. , Koenig, Julie L. , Sakthivel, Ku G., Gao, Sarah , Rahbi, Nasser Al, Sridhar, Akshay , Shah, Nimish , Osborne, Wendy , Chang, Isabela , Miall, Fiona , Mikhaeel, G., Penn, Anthony, Pepa, Roberta Della , Opat, Stephen , Tedjaseputra, Aditya , Palese, Monica , Kelly, Kara M. , Binkley, Michael Sargent , Major, Ajay , Hopkins, David , Ng, Andrea , Casulo, Carla , Baron, Jonathan , Roberts, Kenneth B , Al Kendi, Jalila , Ricardi, Umberto , Torka, Pallawi , Specht, Lena , De Silva, Ravindu , Pickard, Keir , Blazin, Lindsay J , Smith, Christine M , Brady, Jessica , Senchenko, Maria Anatolevna , Hoppe, Bradford S , Terezakis, Stephanie A , Hawkes, Eliza , Doo, Nicole Wong , Barraclough, Allison , Cheah, Chan Yoon , Ku, Matthew , Hamad, Nada , Gilbertson, Michael , Marconi, Tamara , Maurer, Matthew , Eichenauer, Dennis A , Hoppe, Richard T , Savage, Kerry J , Advani, Ranjana H , Opat, Stephen , Dickinson, Michael , Flerlage, Jamie E , Prica, Anca A. , Casulo, Carla , Blazin, Lindsay , Henry, Michael, Halperin, Daniel M. , Hoppe, Bradford S. , Talaulikar, Dipti , Picardi, Marco , Kirova, Youlia , Doo, Nicole Wong , Hamad, Nada , Maurer, Matthew J. , Eichenauer, Dennis A. , Hodgson, David C. , Rauf, M. Shahzad , Maghfoor, Irfan , Pinnix, Chelsea C. , Vega, Francisco , Alomari, Mohammed, Collins, Graham P. , Tsang, Richard , Kelsey, Chris R. , McKay, Pamela , Constine, Louis S , Plastaras, John Peter , Levis, Mario , Sridhar, Akshay, Volchkov, Egor Vasilevich , Northend, Michael , Salvaris, Ross , Shankar, Ananth , Natkunam, Yasodha

Mayo Clinic

Journal of Clinical Oncology | March 26, 2024 | Volume: 42 | Issue: 19 | Pages: 2271-2280

10.1200/jco.23.01655 | PMID 38531001 Get It

PURPOSE Nodular lymphocyte–predominant Hodgkin lymphoma (NLPHL) is a rare cancer, and large international cooperative efforts are needed to evaluate the significance of clinical risk factors and immunoarchitectural patterns (IAPs) for all stages of pediatric and adult patients with NLPHL. METHODS Thirty-eight institutions participated in the Global nLPHL One Working Group retrospective study of NLPHL cases from 1992 to 2021. We measured progression-free survival (PFS), overall survival (OS), transformation rate, and lymphoma-specific death rate. We performed uni- and multivariable (MVA) Cox regression stratified by management to select factors for the lymphocyte-predominant international prognostic score (LP-IPS) validated by five-fold cross-validation. RESULTS We identified 2,243 patients with a median age of 37 years (IQR, 23-51). The median follow-up was 6.3 years (IQR, 3.4-10.8). Most had stage I to II (72.9%) and few B symptoms (9.9%) or splenic involvement (5.4%). IAP was scored for 916 (40.8%). Frontline management included chemotherapy alone (32.4%), combined modality therapy (30.5%), radiotherapy alone (24.0%), observation after excision (4.6%), rituximab alone (4.0%), active surveillance (3.4%), and rituximab and radiotherapy (1.1%). The PFS, OS, transformation, and lymphoma-specific death rates at 10 years were 70.8%, 91.6%, 4.8%, and 3.3%, respectively. On MVA, IAPs were not associated with PFS or OS, but IAP E had higher risk of transformation (hazard ratio [HR], 1.81; P < .05). We developed the LP-IPS with 1 point each for age ≥45 years, stage III-IV, hemoglobin <10.5 g/dL, and splenic involvement. Increasing LP-IPS was significantly associated with worse PFS (HR, 1.52) and OS (HR, 2.31) and increased risk of lymphoma-specific death (HR, 2.63) and transformation (HR, 1.41). CONCLUSION In this comprehensive study of all ages of patients with NLPHL, we develop the LP-IPS to identify high-risk patients and inform upcoming prospective clinical trials evaluating de-escalation of therapy for patients with low LP-IPS scores (<2).
THE PROGNOSTIC IMPACT OF CLINICAL FACTORS AND IMMUNOARCHITECTURAL PATTERNS FOR NODULAR LYMPHOCYTE‐PREDOMINANT HODGKIN LYMPHOMA: AN INTERNATIONAL STUDY BY GLOW
Binkley, Michael S., Borchmann, Peter , Fuchs, Michael , Hartmann, Sylvia , Eich, Hans Theodor, Skinnider, Brian, Steiner, Raphaël , Milgrom, Sarah A. , Alomari, Mohammed H., Zhang, Xieyi , Advani, Ranjana H. , Metzger, Monika L. , Wirth, A., Smith, Sonali M. , Hendrickson, P., Hopkins, David , Ng, Andrea K. , Koenig, Julie L. , Sakthivel, GD, Roberts, Kenneth B. , Gao, Sarah , Kendi, J. Al, Rahbi, Nasser Al, Balogh, Alex, Torka, Pallawi , Silva, Ravi De , Shah, Nimish , Osborne, Wendy , Henry, M M , Chang, Ilsung , Miall, Fiona , Brady, J.L. , Mikhaeel, G., Brennan, Barbara J. , Penn, Andrew M. , Сенченко, М. А. , Reeves, Mark E. , Terezakis, Stephanie , Fergusson, Pamela, Kelly, Kara M. , Advani, Ranjana H , Hopkins, David , Senchenko, Maria Anatolevna , Binkley, Michael S. , Flerlage, Jamie E. , Savage, Kerry J. , Hodgson, David C. , Akhtar, Saad , Rauf, M. Shahzad , Maghfoor, Irfan , Pinnix, Chelsea C. , Vega, Francisco , Alomari, M., Zhang, X., Collins, Graham P. , Dickinson, Michael , Tsang, Richard , Prica, Anca A. , Major, Ajay , Kelsey, Chris R. , McKay, Pamela , Constine, Louis S , Casulo, Carla , Baron, J., Plastaras, John Peter , Kendi, J. Al, Levis, Mario , Ricardi, Umberto , Sridhar, A., Specht, Lena , Pickard, Keir , Blazin, Lindsay , Henry, M., Chang, I., Smith, Christine M , Halperin, Daniel M. , Brennan, B., Penn, A., Volchkov, Egor Vasilevich , Reeves, M., Hoppe, Bradford S. , Talaulikar, Dipti , Pepa, Roberta Della , Picardi, Marco , Kirova, Youlia , Fergusson, P., Northend, Michael , Shankar, Ananth , Maurer, Matthew J. , Natkunam, Yasodha , Eichenauer, Dennis A. , Hoppe, Richard T.

Mayo Clinic

Hematological Oncology | June 9, 2023 | Volume: 41 | Issue: S2 | Pages: 100-101

10.1002/hon.3163_62 Get It

Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG
Binkley, Michael S. , Milgrom, Sarah A. , Dickinson, Michael , Ng, Andrea K. , Roberts, Kenneth B. , Gao, Sarah , Balogh, Alex, Levis, Mario , Casulo, Carla , Stolten, Michael , Specht, Lena , Wright, Christopher M. , Brady, J.L. , Mikhaeel, N. George , Terezakis, Stephanie , Pepa, Roberta Della , Maghfoor, Irfan , Koenig, Julie L. , Jackson, Christopher , Song, Erin J. , Sehgal, Shuchi, Advani, Ranjana H. , Natkunam, Yasodha , Eich, Hans Theodor, Wirth, Andrew, Hoppe, Richard T. , Advani, Ranjana H , Dickinson, Michael , Binkley, Michael Sargent , Specht, Lena , Hoppe, Richard T , Natkunam, Yasodha , Levis, Mario , Rauf, M. Shahzad , Pinnix, Chelsea C. , Tsang, Richard , Ricardi, Umberto , Casulo, Carla , Plastaras, John Peter , Kelsey, Chris R. , Hoppe, Bradford S. , Picardi, Marco , Kirova, Youlia , Akhtar, Saad , Constine, Louis S

Mayo Clinic

Blood | March 25, 2020 | Volume: 135 | Issue: 26 | Pages: 2365-2374

10.1182/blood.2019003877 | PMID 32211877 Get It

Abstract Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is an uncommon histologic variant, and the optimal treatment of stage I-II NLPHL is undefined. We conducted a multicenter retrospective study including patients ≥16 years of age with stage I-II NLPHL diagnosed from 1995 through 2018 who underwent all forms of management, including radiotherapy (RT), combined modality therapy (CMT; RT+chemotherapy [CT]), CT, observation after excision, rituximab and RT, and single-agent rituximab. End points were progression-free survival (PFS), freedom from transformation, and overall survival (OS) without statistical comparison between management groups. We identified 559 patients with median age of 39 years: 72.3% were men, and 54.9% had stage I disease. Median follow-up was 5.5 years (interquartile range, 3.1-10.1). Five-year PFS and OS in the entire cohort were 87.1% and 98.3%, respectively. Primary management was RT alone (n = 257; 46.0%), CMT (n = 184; 32.9%), CT alone (n = 47; 8.4%), observation (n = 37; 6.6%), rituximab and RT (n = 19; 3.4%), and rituximab alone (n = 15; 2.7%). The 5-year PFS rates were 91.1% after RT, 90.5% after CMT, 77.8% after CT, 73.5% after observation, 80.8% after rituximab and RT, and 38.5% after rituximab alone. In the RT cohort, but not the CMT cohort, variant immunoarchitectural pattern and number of sites &gt;2 were associated with worse PFS (P &lt; .05). Overall, 21 patients (3.8%) developed large-cell transformation, with a significantly higher transformation rate in those with variant immunoarchitectural pattern (P = .049) and number of involved sites &gt;2 (P = .0006). OS for patients with stage I-II NLPHL was excellent after all treatments.